Eledon Pharmaceuticals, Inc. (ELDN): Price and Financial Metrics


Eledon Pharmaceuticals, Inc. (ELDN): $3.29

-0.03 (-0.90%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ELDN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ELDN Stock Price Chart Interactive Chart >

Price chart for ELDN

ELDN Price/Volume Stats

Current price $3.29 52-week high $4.39
Prev. close $3.32 52-week low $2.03
Day low $3.24 Volume 5,354
Day high $3.37 Avg. volume 18,794
50-day MA $2.68 Dividend yield N/A
200-day MA $2.90 Market Cap 45.26M

Eledon Pharmaceuticals, Inc. (ELDN) Company Bio


Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.


ELDN Latest News Stream


Event/Time News Detail
Loading, please wait...

ELDN Latest Social Stream


Loading social stream, please wait...

View Full ELDN Social Stream

Latest ELDN News From Around the Web

Below are the latest news stories about ELEDON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ELDN as an investment opportunity.

Eledon Pharmaceuticals Provides Business and Pipeline Updates

Company plans to prioritize and focus resources on the advancement of tegoprubart in kidney transplantation Continued enrollment in open-label Phase 1b kidney transplant trial with initial data release expected at the World Congress of Nephrology in March 2023 Phase 2 BESTOW trial planned to evaluate tegoprubart for the prevention of rejection in patients receiving a kidney transplant with site initiation anticipated in mid-2023 Deprioritize clinical development of tegoprubart in IgA Nephropathy

Yahoo | January 9, 2023

eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies

-Agreement leverages Eledon’s investigational anti-CD40L antibody, tegoprubart, as part of eGenesis’ immunosuppression regimen that prevents xenotransplant rejection in nonhuman primate recipients- -Establishes framework for use of tegoprubart for preclinical xenotransplantation studies in support of eGenesis’ kidney, heart and islet cell programs- CAMBRIDGE, Mass. and IRVINE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- eGenesis, Inc. (“eGenesis”) and Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDA

Yahoo | January 9, 2023

C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System

Eledon to Incorporate the iBox Scoring System in Future Kidney Transplant TrialsIRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path) announced on December 20, 2022, that its Transplant Therapeutic Consortium (TTC) received a qualification opinion for the iBox Scoring System as a novel secondary efficacy endpoint for kidney transplant clinical trials through the European Medicines Agency's (EMA) qualification of novel methodologies for drug development. This novel se

Yahoo | December 21, 2022

Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results

Received FDA clearance of IND application to evaluate tegoprubart in a Phase 2 trial for the prevention of rejection in patients receiving a kidney transplant Dosed initial two patients in ex-U.S. Phase 1b trial evaluating tegoprubart for the prevention of rejection in patients receiving a kidney transplant Received FDA clearance of IND application to evaluate tegoprubart for the treatment of IgA Nephropathy (IgAN) Conference call today at 4:30 PM ET IRVINE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE

Yahoo | November 14, 2022

Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Management to host conference call and webcast at 4:30 pm ETIRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it plans to release financial results for the third quarter ended September 30, 2022 on Monday, November 14, after the close of trading. Eledon’s management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Details:Monday, November 14, 2022 at 4:30 p.m. Eastern T

Yahoo | November 3, 2022

Read More 'ELDN' Stories Here

ELDN Price Returns

1-mo 51.61%
3-mo 42.42%
6-mo 9.30%
1-year -7.58%
3-year -67.36%
5-year N/A
YTD 44.30%
2022 -48.30%
2021 -71.36%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7331 seconds.